About: A Novel MVA Vectored Chikungunya Virus Vaccine Elicits Protective Immunity in Mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A Novel MVA Vectored Chikungunya Virus Vaccine Elicits Protective Immunity in Mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A Novel MVA Vectored Chikungunya Virus Vaccine Elicits Protective Immunity in Mice
Creator	Chu, Haiyan Weger-Lucarelli, James Aliota, Matthew Osorio, Jorge Partidos, Charalambos
Source	PMC
abstract	BACKGROUND: Chikungunya virus (CHIKV) is a re-emerging arbovirus associated with febrile illness often accompanied by rash and arthralgia that may persist for several years. Outbreaks are associated with high morbidity and create a public health challenge for countries affected. Recent outbreaks have occurred in both Europe and the Americas, suggesting CHIKV may continue to spread. Despite the sustained threat of the virus, there is no approved vaccine or antiviral therapy against CHIKV. Therefore, it is critical to develop a vaccine that is both well tolerated and highly protective. METHODOLOGY/PRINCIPAL FINDINGS: In this study, we describe the construction and characterization of a modified Vaccinia virus Ankara (MVA) virus expressing CHIKV E3 and E2 proteins (MVA-CHIK) that protected several mouse models from challenge with CHIKV. In particular, BALB/c mice were completely protected against viremia upon challenge with CHIKV after two doses of MVA-CHIK. Additionally, A129 mice (deficient in IFNα/β) were protected from viremia, footpad swelling, and mortality. While high anti-virus antibodies were elicited, low or undetectable levels of neutralizing antibodies were produced in both mouse models. However, passive transfer of MVA-CHIK immune serum to naïve mice did not protect against mortality, suggesting that antibodies may not be the main effectors of protection afforded by MVA-CHIK. Furthermore, depletion of CD4(+), but not CD8(+) T-cells from vaccinated mice resulted in 100% mortality, implicating the indispensable role of CD4(+) T-cells in the protection afforded by MVA-CHIK. CONCLUSIONS/SIGNIFICANCE: The results presented herein demonstrate the potential of MVA to effectively express CHIKV E3-E2 proteins and generate protective immune responses. Our findings challenge the assumption that only neutralizing antibodies are effective in providing protection against CHIKV, and provides a framework for the development of novel, more effective vaccine strategies to combat CHIKV.
has issue date	2014-07-24(xsd:dateTime)
bibo:doi	10.1371/journal.pntd.0002970
bibo:pmid	25058320
has license	cc-by
sha1sum (hex)	3aa75376556fa96324ad4cacb0b862ad86b7a11e
schema:url	https://doi.org/10.1371/journal.pntd.0002970
resource representing a document's title	A Novel MVA Vectored Chikungunya Virus Vaccine Elicits Protective Immunity in Mice
has PubMed Central identifier	PMC4109897
has PubMed identifier	25058320
schema:publication	PLoS Negl Trop Dis
resource representing a document's body	covid:3aa75376556fa96324ad4cacb0b862ad86b7a11e#body_text
is schema:about of	named entity 'rash' named entity 'Chikungunya virus' named entity 'Europe' named entity 'CHIKV' named entity 'Chikungunya' named entity 'PROTECTIVE IMMUNITY' named entity 'OCCURRED' named entity 'HAVE' named entity 'CRITICAL' named entity 'MORBIDITY' named entity 'SUSTAINED' named entity 'HIGH' named entity 'IS A' named entity 'CREATE' named entity 'RASH' named entity 'APPROVED' named entity 'MVA' named entity 'CHALLENGE' named entity 'CONTINUE' named entity 'VACCINE' named entity 'MICE' named entity 'CHIKUNGUNYA VIRUS VACCINE' named entity 'ELICITS' named entity 'VECTORED' named entity 'BACKGROUND' named entity 'RECENT' named entity 'COUNTRIES' named entity 'PUBLIC HEALTH' named entity 'ANTIVIRAL THERAPY' named entity 'ARBOVIRUS' named entity 'SPREAD' named entity 'FEBRILE ILLNESS' named entity 'AFFECTED' named entity 'AMERICAS' named entity 'EUROPE' named entity 'THREAT' named entity 'ARTHRALGIA' named entity 'NOVEL' named entity 'VIRUS' named entity 'YEARS' named entity 'OUTBREAKS' named entity 'ASSOCIATED WITH' named entity 'CHIKUNGUNYA VIRUS' covid:arg/3aa75376556fa96324ad4cacb0b862ad86b7a11e named entity 'arbovirus' named entity 'Despite' named entity 'CD4' named entity 'p62' named entity 'P-values' named entity 'protein' named entity 'high fever' named entity 'smallpox' named entity 'PBS' named entity 'paraformaldehyde' named entity 'adenovirus' named entity 'Roche Diagnostics' named entity 'mosquitoes' named entity 'ELISAs' named entity 'parasite' named entity 'cell-mediated' named entity 'Bio-Rad' named entity 'CD4' named entity 'animal experiments' named entity 'CD4+ T-cells' named entity 'wild-type' named entity 'virus' named entity 'mice' named entity 'mice' named entity 'antibodies' named entity 'recombinant virus' named entity 'pH 9' named entity 'TNF-a' named entity 'virus' named entity 'vaccination' named entity 'CHIKV' named entity 'CD4' named entity 'T-cells'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software